Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients" International Study.
Sollena P, Vasiliki N, Kotteas E, Stratigos AJ, Fattore D, Orlandi A, Mannino M, Di Pumpo M, Fida M, Starace M, Apalla Z, Romano MC, Riganti J, Segura S, Martinez AF, Fabbrocini G, Sibaud V, Peris K, On Behalf Of The Eadv Task Force Dermatology For Cancer Patients. Sollena P, et al. Among authors: kotteas e. Cancers (Basel). 2023 Jul 18;15(14):3658. doi: 10.3390/cancers15143658. Cancers (Basel). 2023. PMID: 37509319 Free PMC article.
Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.
Sollena P, Nikolaou V, Soupos N, Kotteas E, Voudouri D, Stratigos AJ, Fattore D, Annunziata MC, Orlandi A, Di Nardo L, Apalla Z, Deilhes F, Romano MC, Fabbrocini G, Sibaud V, Peris K; European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group. Sollena P, et al. Among authors: kotteas e. Breast Cancer Res Treat. 2021 Jan;185(1):247-253. doi: 10.1007/s10549-020-05914-w. Epub 2020 Sep 10. Breast Cancer Res Treat. 2021. PMID: 32914354
Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
Gomatou G, Trontzas I, Ioannou S, Drizou M, Syrigos N, Kotteas E. Gomatou G, et al. Among authors: kotteas e. Mol Biol Rep. 2021 Jan;48(1):915-925. doi: 10.1007/s11033-020-06100-3. Epub 2021 Jan 7. Mol Biol Rep. 2021. PMID: 33409716 Review.
Progress and Challenges of Messenger RNA Vaccines in the Therapeutics of NSCLC.
Kiousi E, Lyraraki V, Mardiki GL, Stachika N, Damianou AK, Malainou CP, Syrigos N, Gomatou G, Kotteas E. Kiousi E, et al. Among authors: kotteas e. Cancers (Basel). 2023 Nov 26;15(23):5589. doi: 10.3390/cancers15235589. Cancers (Basel). 2023. PMID: 38067293 Free PMC article. Review.
76 results